Pfizer (PFE) Finished Goods (2009 - 2019)

Pfizer has disclosed Finished Goods across 11 years of filings, most recently posting $2.3 billion for Q1 2019.

• In Q1 2019, Finished Goods fell 19.42% year-over-year to $2.3 billion; the TTM figure through Mar 2019 stood at $2.3 billion (down 19.42% YoY), while the FY2018 annual figure was $2.3 billion, down 21.54% from the prior year.
• Finished Goods grew to $2.3 billion in Q1 2019, from $2.3 billion in the prior quarter.
• Over the last five years, Finished Goods for PFE reached as high as $2.9 billion in Q4 2017 and fell as low as $1.8 billion in Q2 2015.
• The 5-year median for Finished Goods is $2.6 billion (2016), against an average of $2.5 billion.
• Annual changes were most pronounced in 2015 — Finished Goods decreased 24.86% — and 2016, when it surged 49.89%.
• A 5-year view of Finished Goods shows it stood at $2.7 billion in 2015, then retreated by 15.51% to $2.3 billion in 2016, then increased by 25.73% to $2.9 billion in 2017, then slipped by 21.54% to $2.3 billion in 2018, then gained by 1.11% to $2.3 billion in 2019.
• According to Business Quant data, Finished Goods over the past three periods registered $2.3 billion, $2.3 billion, and $2.6 billion for Q1 2019, Q4 2018, and Q3 2018 respectively.